MedTrace Logo

Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia

NCT02964923 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2016-11-16

No results posted yet for this study

Summary

The purpose of the study is to investigate these effects of Second-Generation Antipsychotic (SGAs) on glucose and lipid metabolic parameters in patients with schizophrenia, and explore the relationship between genes polymorphisms (such as drug metabolic enzyme, Endogenous Cannabinoid Receptor Type 1(CB1) and so on) and the SGAs-induced glucose and lipid metabolic disorder in Chinese Han persons with schizophrenia who are taking one of the SGAs(olanzapine, risperidone or ziprasidone).

Conditions

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Huaning Wang, Ph.D · Department of Psychiatry,Xijing hospital,Xi'an,China

  • Zhifu Yang, Ph.D · Department of Pharmacy,Xijing hospital,Xi'an,China

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02964923 on ClinicalTrials.gov